Good MorningInvestors continue to bet on growth despite the rising specter of inflation. The S&P 500 reversed early losses on Wednesday to close with a small gain going into the holiday weekend. The move is the 15th day of trading within a near-term consolidation range that is fast becoming a bullish-looking flag pattern. If the market breaks out to the upside and confirms this pattern within the next week or so it should rally well into the end of the year.
In economic news, the PCE Price Index was released on Wednesday coming in largely as expected. The rub is that “as expected” included a 0.20% month-to-month increase and the fastest pace of YOY gains for several decades. At this pace, the market should expect the first interest rate hikes to come well before the middle of next year.
Featured: Billionaire Trader Warns: Get Out of Stocks (Ad) 
|
Energy | | Despite attention on green energy, oil-and-gas stocks such as EOG Resources (NYSE: EOG), Callon Petroleum (NYSE: CPE) and Matador Resources (NYSE: MTDR) all traded higher this week, and all found support at a key moving average.
Despite efforts to move away from fossil fuels, that won’t happ... Read the Full Story |
|
From Our Partners | | Why Some Traders Skip Stocks Entirely
You don't need a big account to trade options.
In fact, options can give you up to 12 times the leverage of stocks — with a fraction of the capital tied up.
This free guide lays it all out in plain English — from A to Z, with step-by-step examples you can follow in your own account. | | Normally $29.97. Today it's free. Grab your copy now. |
|
Markets | |
Suspect that you might need a financial advisor or financial planner? Deciding whether to add a financial advisor to your "team" might depend on a variety of reasons, both personal and practical. The end of the year might be the right time to search for your newest team member.
In a CNBC and Acor... Read the Full Story |
|
Technology | |
Take Another Nibble Of These Three Hot Stocks
Now the holiday feasting is over it’s time to get back to business. With the New Year just around the corner, the business at hand is preparing for the coming year. The outlook for earnings growth is tepid and marred by inflation but not all co... Read the Full Story |
|
From Our Partners | | After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to trigger the next crash. The research firm Bernstein Research said this AI company has the power to crash the global economy for a decade, the CEO just issued a CODE RED in an internal memo warning employees they're dealing with a critical situation, and another company executive even implied they might need a government bailout. The last time I saw something like this was in 2008 when I predicted a stock market meltdown just three weeks before Lehman went under. | | See the five simple steps to prepare before it's too late |
|
Technology | | With November shaping up to be yet another record setting month for U.S. stocks, it’s time to look ahead at what December may bring. While predicting near term market movements is difficult, like last year, there’s a good chance this month’s run turns into a Santa Claus rally. As h... Read the Full Story |
|
Technology | |
The Year Of The IPO Isn’t Over Yet
This year has been a busy year for IPO’s. If there is one thing we’ve learned it’s that rushing in to buy an IPO on the first day, or even within the first few days, isn’t always the smartest thing to do, even when the underlying c... Read the Full Story |
|
From Our Partners | | Roger Scott spent over three decades trading through the dot-com bust, the financial crisis, the COVID crash, and last year's tariff-driven selloff - managing two hedge funds along the way.
Now he's sharing the day-trading rules he rarely discusses publicly, including how to identify stocks already moving higher and the criteria behind a 94.5% win rate. | | Access Roger Scott's free day-trading report now |
|
Consumer Staples | |
Undervalued J.M. Smucker Company Has Multiple Expansion In-Play
J.M. Smucker Company’s (NYSE: SJM) Q2 results are not without issue but what issues there are can be overlooked in favor of pricing power. While inflationary issues are cutting into bottom-line results, the cut was less severe ... Read the Full Story |
|
Retail/Wholesale | |
Pricing Power Lifts Burlington Stores
Shares of Burlington Stores (NYSE: BURL) experienced a bit of volatility in the wake of the Q3 report that had the first down 5.0% in premarket action and then up more than 8.0% by the close of the session. The move was driven by inflationary woes that were ... Read the Full Story |
|
Retail/Wholesale | |
Insider Ownership In Movado Group Still Strong After Selling
Insiders were selling shares of Movado Group (NYSE: MOV) earlier this year but it is nothing for investors to worry about. Selling was broad-based among top execs, if centered on the company’s CEO, and amounted to less than 0.35%... Read the Full Story |
|
Industrials | |
Deere & Company Exit Uncertain Times
After several quarters of range-bound trading and market uncertainty, it looks like shares of Deere & Company (NYSE: DE) are about to run higher. Not only has the company exceeded its fiscal 2021 expectations but a major strike has been resolved and t... Read the Full Story |
|
Markets | |
It's almost Thanksgiving, and at least one well-intentioned family member will invariably ask your high school senior, "Where are you going to college next year?" (In fact, you might want to warn your high schooler in advance.)
The College Board published the 2021-2022 average sticker price for t... Read the Full Story |
|
The Early Bird Stock Of The Day Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California. | | View Today's Stock Pick |
|
